News
US virtual medical practice raises US$33m to improve maternal and newborn health
The US has some of the highest rates of preterm birth, NICU admissions and preventable maternal complications
The US virtual medical practice Pomelo Care has raised US$33m in funding to improve maternal and newborn health outcomes.
The round, led by Andreessen Horowitz, is hoped to help Pomelo expand its partnerships with major health plans, including several Medicaid managed care organisations, employers as well as academic medical centres.
Pomelo’s multispecialty team of expert clinicians cares for mothers and infants from preconception through pregnancy, birth and one year postpartum.
Its virtual care model, the company says, pairs each patient with a care team to address maternal health inequities and the root causes of poor outcomes.
The platform uses data to predict and proactively identify risk, providing holistic care.
“We know that the right care at the right time can dramatically improve outcomes for families,” said Marta Bralic Kerns, founder and CEO at Pomelo Care.
“Everyone deserves access to high-quality care, regardless of their circumstances or health plan.
“That’s why Pomelo exists – we address patient concerns right away and at home, keeping them out of the emergency room unnecessarily and lowering their risk of pregnancy, postpartum and newborn complications.”
Despite spending US$111b annually on maternal healthcare, the US has some of the highest rates of preterm birth, NICU admissions and preventable maternal complications in the developed world.
Maternal mortality worsened during the pandemic, data suggests, with poor maternal and newborn outcomes remaining even more common in communities of color and rural areas.
One in ten newborns start their life in the NICU and cesarean births have increased 41 per cent over the last two decades.
However, Pomelo says, with the right interventions, preterm births can be reduced by 33 per cent, cesarean deliveries reduced by 40 per cent and the average NICU stay reduced by at least four days.
Vineeta Agarwala, general partner at Andreessen Horowitz, said: “It’s inexcusable that women in the US face one of the highest national mortality rates from preventable complications during pregnancy – and this statistic is only worsening year over year due to social disparities and systemic gaps in care delivery and access.
“Pomelo’s technology-driven, value-based care model completely reimagines how new families access high-quality specialty care and achieve better outcomes while also reducing costs for our leading health plans, health systems and employers.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment